Risk factors for adverse outcomes in elderly patients with asthma and severe COVID-19 at the hospital and early post-hospital stages

Cover Page

Cite item

Full Text

Abstract

Background. Mortality and COVID-19 related factors are thoroughly analyzed. Given the large number of hospitalized patients, the potential short- and long-term COVID-19 related complications, further research is needed on the possible consequences of hospitalization, especially in higher-risk patients, after prolonged hospitalization and intensive care admission.

Aim. To study the clinical course and outcomes of severe COVID-19 in elderly patients with asthma at the hospital and early post-hospital stages.

Materials and methods. The study included 131 elderly patients (WHO, 2020) >60 years old, n=131 with asthma, hospitalized for severe COVID-19. Of these, 86 (65.6%) patients survived, 30 (22.9%) died in the hospital, and 15 (14.9%) patients died after discharge from the hospital (in the 90-day post-hospital period). COVID-19 was confirmed by laboratory tests (SARS-CoV-2 PCR RNA test) and/or clinically and radiologically. All patients had a documented history of asthma. Patients were followed up during the hospital stay and for 90 days after discharge.

Results. Comparison of outcomes showed that in the groups of patients with a fatal outcome (regardless of the stage), the Charlson comorbidity index, respiratory rate, extent of lung damage assessed by computed tomography, the absolute leukocyte and neutrophil number and the ratio of neutrophils to lymphocytes were statistically significantly higher. The absolute number of eosinophils was lower in these groups. In the group of patients who died during hospitalization, severe (IV–V) asthma (p=0.03), steroid use during the previous year (p=0.02), chronic heart failure with a reduced ejection fraction (p=0.009) were more common, and atopic asthma phenotype was less common (p=0.02). In those who died after discharge, more common were non-invasive ventilation and diabetes mellitus (p<0.001). The multivariate regression analysis model revealed the most significant predictors of mortality at the hospital and early post-hospital stages.

Conclusion. Adverse outcomes of severe COVID-19 in elderly patients with asthma include hospital and post-hospital mortality. The most significant predictors of mortality are the comorbidity index and low eosinophil count. Hospital mortality is associated with a higher ratio of neutrophils to lymphocytes and lower total protein levels; early (90-day) post-hospital mortality is associated with extensive lung damage shown by computed tomography and diabetes mellitus.

About the authors

Sergey N. Avdeev

Sechenov First Moscow State Medical University (Sechenov University); Pulmonology Research Institute

Email: ivv_08@mail.ru
ORCID iD: 0000-0002-5999-2150

акад. РАН, д-р мед. наук, проф., зав. каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского; рук. клинического отд.

Russian Federation, Moscow; Moscow

Viliya V. Gaynitdinova

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: ivv_08@mail.ru
ORCID iD: 0000-0001-9928-926X

д-р мед. наук, проф. каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Anna A. Pozdniakova

University Clinical Hospital № 4 of Sechenov First Moscow State Medical University (Sechenov University)

Email: ivv_08@mail.ru
ORCID iD: 0000-0001-9125-1873

врач-терапевт приемного отд-ния

Russian Federation, Moscow

Anna E. Vlasenko

Novokuznetsk State Institute Doctors’ Improvements – branch of Russian Medical Academy of Continuous Professional Education

Email: ivv_08@mail.ru
ORCID iD: 0000-0001-6454-4216

канд. техн. наук, преподаватель каф. медицинской кибернетики и информатики

Russian Federation, Novokuznetsk

Tatiana Iu. Gneusheva

Sechenov First Moscow State Medical University (Sechenov University)

Email: ivv_08@mail.ru
ORCID iD: 0000-0002-6757-8961

канд. мед. наук, ассистент каф. пульмонологии Института клинической медицины им. Н.В. Склифосовского

Russian Federation, Moscow

Irina V. Baytemerova

City Clinical Hospital №5

Email: ivv_08@mail.ru
ORCID iD: 0000-0001-7277-5284

врач-пульмонолог

Russian Federation, Ufa

References

  1. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-9. doi: 10.1016/j.jiph.2020.07.014
  2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-42. doi: 10.1001/jama.2020.2648
  3. Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2000547. doi: 10.1183/13993003.00547-2020
  4. Eger K, Bel EH. Asthma and COVID-19: do we finally have answers? Eur Respir J. 2021;57(3):2004451. doi: 10.1183/13993003.04451-2020
  5. Butler MW, O'Reilly A, Dunican EM, et al. Prevalence of comorbid asthma in COVID-19 patients. J Allergy Clin Immunol. 2020;146:334-5. doi: 10.21037/jtd.2017.08.109
  6. Choi H-G, Wee JH, Kim SY, et al. Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control & Prevention. Allergy. 2021;76(3):921-4. doi: 10.1111/all.14675
  7. Eggert LE, He Z, Collins W, et al. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy. 2022;77(1):173-85. doi: 10.1111/all.14972
  8. Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146(6):1295-301. doi: 10.1016/j.jaci.2020.09.017
  9. Yang JM, Koh HY, Moon SY, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020;146:790-8. doi: 10.1016/j.jaci.2020.08.008
  10. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146:307-14. doi: 10.1016/j.jaci.2020.06.010
  11. Lieberman-Cribbin W, Rapp J, Alpert N, et al. The impact of asthma on mortality in patients with COVID-19. Chest. 2020;194:2019-20. doi: 10.1016/j.chest.2020.05.575
  12. Milanese M, Di Marco F, Corsico AG, et al; ELSA Study Group. Asthma control in elderly asthmatics. An Italian observational study. Respir Med. 2014;108(8):1091-9. doi: 10.1016/j.rmed.2014.05.016
  13. Временные клинические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) Минздрава РФ. Версия 9 (26.10.2020). Режим доступа: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062. Ссылка активна на 02.04.2022 [Vremennye klinicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19) Minzdrava RF. Versiia 9 (26.10.2020). Available at: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062. Accessed: 02.04.2022 (in Russian)].
  14. GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/2020. Accessed: 02.04.2022.
  15. James KM, Peebles RS Jr, Hartert TV. Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility? J Allergy Clin Immunol. 2012;130(2):343-51. doi: 10.1016/j.jaci.2012.05.056
  16. Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57:2002226. doi: 10.1183/13993003.02226-2020
  17. Romero-Duarte Á, Rivera-Izquierdo M, Guerrero-Fernández de Alba I, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19(1):129. doi: 10.1186/s12916-021-02003-7
  18. Fernando SM, McIsaac DI, Rochwerg B, et al. Frailty and invasive mechanical ventilation: association with outcomes, extubation failure, and tracheostomy. Intensive Care Med. 2019;45(12):1742-52. doi: 10.1007/s00134-019-05795-8
  19. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4-6. doi: 10.1016/j.jinf.2020.08.029
  20. Rosales-Castillo A, García de Los Ríos C, Mediavilla García JD. Persistent symptoms after acute COVID-19 infection: importance of follow-up. Med Clin (Barc). 2021;156:35-6. doi: 10.1016/j.medcli.2020.08.001
  21. Carfì A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-5. doi: 10.1001/jama.2020.12603
  22. Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020. doi: 10.1183/23120541.00542-2020
  23. Zhu Y, Zhang J, Li Y, et al. Association between thrombocytopenia and 180-day prognosis of COVID-19 patients in intensive care units: A two-center observational study. PLoS One. 2021;16(3):e0248671. doi: 10.1371/journal.pone.0248671

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. The distribution of parameters associated with mortality at the hospital and post-hospital stages in the study groups.

Download (526KB)
3. Fig. 2. Survival curves of patients with COVID-19 and asthma depending on the eosinophil count: a – at the hospital stage (follow-up period of 28 days); b – at the early post-hospital stage (follow-up period of 90 days).

Download (247KB)
4. Fig. 3. Correlations between individual parameters (overall sample, n=131) and the Spearman correlation coefficient were calculated, and the linear approximation was performed using the robust regression method.

Download (343KB)
5. Fig. 4. Factors associated with a high mortality risk at the hospital stage with the relative risks and 95% confidence intervals. The relative risk is calculated per unit of measure, unless otherwise specified.

Download (154KB)
6. Fig. 5. Factors associated with a high mortality risk at the post-hospital stage with the relative risks and 95% confidence intervals. The relative risk is calculated per unit of measure, unless otherwise specified.

Download (106KB)

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies